Marcello Moccia1, Roberto Erro2,3, Marina Picillo4,5, Gabriella Santangelo6,7, Emanuele Spina1, Roberto Allocca1, Katia Longo7, Marianna Amboni7, Raffaele Palladino8,9, Roberta Assante10, Sabina Pappatà11, Maria Teresa Pellecchia4, Paolo Barone4, Carmine Vitale7,12. 1. Department of Neurosciences, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy. 2. Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, London, UK. 3. Department of Neurological and Movement Sciences, University of Verona, Policlinico Borgo Roma, Verona, Italy. 4. Center for Neurodegenerative Diseases (CEMAND), Neuroscience Section, Department of Medicine, University of Salerno, Salerno, Italy. 5. Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Division of Neurology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. 6. Department of Psychology, Neuropsychology Laboratory, Second University of Naples, Caserta, Italy. 7. IDC Hermitage-Capodimonte, Naples, Italy. 8. Department of Primary Care and Public Health, Imperial College, London, UK. 9. Department of Public Health, Federico II University, Naples, Italy. 10. Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy. 11. Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy. 12. Department of Motor Sciences, University Parthenope, Naples, Italy.
Abstract
STUDY OBJECTIVES: Restless legs syndrome (RLS) prevalence estimates range from 0% to 52% in Parkinson disease (PD), but the causal relationship between the two disorders is still debated. The present study aims to evaluate RLS prevalence in de novo PD subjects, its incidence during the first 4 years from diagnosis, and possible relationships with clinical, laboratory, and neuroradiological data. METHODS: One hundred nine newly diagnosed, drug-naïve PD subjects were evaluated at the time of PD diagnosis, and after 2- and 4-years. RLS diagnosis was performed with the RLS Diagnostic Index at each visit. Motor features, additional non-motor symptoms (NMS), and concomitant dopaminergic and nondopaminergic treatments were also gathered. Moreover, at baseline, 65 subjects were randomly selected to undergo a FP-CIT SPECT to study dopamine transporter availability. RESULTS: RLS prevalence rose from 4.6% at baseline evaluation to 6.5% after 2 years and to 16.3% after 4 years (P = 0.007). A multinomial logistic stepwise regression model selected NMS Questionnaire items more likely to be associated with RLS at diagnosis (insomnia, OR = 15.555; P = 0.040) and with occurrence of RLS during follow-up (dizziness, OR = 1.153; P = 0.022; and daytime sleepiness; OR = 9.557; P = 0.001), as compared to patients without RLS. Older age was more likely associated to increased RLS occurrence during follow-up in a random effect logistic regression model (OR = 1.187; P = 0.036). A multinomial logistic stepwise model found increased dopaminergic transporter availability of affected caudate and putamen to be more likely associated with RLS presence at diagnosis (n = 5; OR = 75.711; P = 0.077), and RLS occurrence during follow-up (n = 16; OR = 12.004; P = 0.059), respectively, as compared to patients without RLS (n = 88). CONCLUSIONS: RLS is present since PD diagnosis, and increases in prevalence during the course of PD. PD subjects with RLS have higher age at PD onset, more preserved dopaminergic pathways, and worse sleep and cardiovascular disturbances.
STUDY OBJECTIVES:Restless legs syndrome (RLS) prevalence estimates range from 0% to 52% in Parkinson disease (PD), but the causal relationship between the two disorders is still debated. The present study aims to evaluate RLS prevalence in de novo PD subjects, its incidence during the first 4 years from diagnosis, and possible relationships with clinical, laboratory, and neuroradiological data. METHODS: One hundred nine newly diagnosed, drug-naïve PD subjects were evaluated at the time of PD diagnosis, and after 2- and 4-years. RLS diagnosis was performed with the RLS Diagnostic Index at each visit. Motor features, additional non-motor symptoms (NMS), and concomitant dopaminergic and nondopaminergic treatments were also gathered. Moreover, at baseline, 65 subjects were randomly selected to undergo a FP-CIT SPECT to study dopamine transporter availability. RESULTS:RLS prevalence rose from 4.6% at baseline evaluation to 6.5% after 2 years and to 16.3% after 4 years (P = 0.007). A multinomial logistic stepwise regression model selected NMS Questionnaire items more likely to be associated with RLS at diagnosis (insomnia, OR = 15.555; P = 0.040) and with occurrence of RLS during follow-up (dizziness, OR = 1.153; P = 0.022; and daytime sleepiness; OR = 9.557; P = 0.001), as compared to patients without RLS. Older age was more likely associated to increased RLS occurrence during follow-up in a random effect logistic regression model (OR = 1.187; P = 0.036). A multinomial logistic stepwise model found increased dopaminergic transporter availability of affected caudate and putamen to be more likely associated with RLS presence at diagnosis (n = 5; OR = 75.711; P = 0.077), and RLS occurrence during follow-up (n = 16; OR = 12.004; P = 0.059), respectively, as compared to patients without RLS (n = 88). CONCLUSIONS:RLS is present since PD diagnosis, and increases in prevalence during the course of PD. PD subjects with RLS have higher age at PD onset, more preserved dopaminergic pathways, and worse sleep and cardiovascular disturbances.
Authors: András Szentkirályi; Henry Völzke; Wolfgang Hoffmann; Claudia Trenkwalder; Klaus Berger Journal: Neurology Date: 2014-05-07 Impact factor: 9.910
Authors: Natalya Shneyder; Charles H Adler; Joseph G Hentz; Holly Shill; John N Caviness; Marwan N Sabbagh; Thomas G Beach; Erika Driver-Dunckley Journal: Sleep Med Date: 2013-09-21 Impact factor: 3.492
Authors: Ariel B Neikrug; Jeanne E Maglione; Lianqi Liu; Loki Natarajan; Julie A Avanzino; Jody Corey-Bloom; Barton W Palmer; Jose S Loredo; Sonia Ancoli-Israel Journal: J Clin Sleep Med Date: 2013-11-15 Impact factor: 4.062
Authors: Roselyne M Rijsman; Louise F Schoolderman; Rob S Rundervoort; Maartje Louter Journal: Parkinsonism Relat Disord Date: 2014-01 Impact factor: 4.891
Authors: Peter C Douris; Zachary S Cogen; Helen T Fields; Lauren C Greco; Matthew R Hasley; Christina M Machado; Peter M Romagnuolo; George Stamboulis; Joanne DiFrancisco-Donoghue Journal: Int J Sports Phys Ther Date: 2018-04